Nutukimas klinikiniai tyrimai Nevada
29 tyrimai dėl Nutukimas ieško dalyvių vietose Nevada.
Miestai Nevada
Oficialus tyrimo tekstas (anglų kalba)
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities
- Vector Clinical Trials /ID# 282265, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-10-02 · NCT07752979A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event
- Excel Clinical Research, LLC, Las Vegas
- Palm Research Center Tenaya, Las Vegas
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-30 · NCT07783802AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Palm Research Center Inc., Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-28 · NCT07720271A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-25 · NCT07776509A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight
- Palm Research Center Tenaya, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07369011Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
- Excel Clinical Research, Las Vegas
- Vector Clinical Trials, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 45 iki 99 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07037433A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
- AMR Clinical, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-22 · NCT07321886A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-22 · NCT07589608A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
- AURORA-1 Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT07743463A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-16 · NCT07743450A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Las Vegas
Renkami dalyviai3 fazėLaukiami sveiki savanoriai
Amžius nuo 18 iki 79 · Visoms lytims · Atnaujinta 2026-09-11 · NCT07654374Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
- Jubilee Clinical Research, Inc., Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-09 · NCT07770841A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
- Las Vegas Medical Research, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-08 · NCT06143956A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
- Vector Clinical Trials, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 75 · Visoms lytims · Atnaujinta 2026-09-08 · NCT07215559A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
- Skin Cancer and Dermatology Institute - Reno, Reno
Renkami dalyviai4 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-04 · NCT06857942Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT07284901Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Palm Research Center Inc, Las Vegas
- Vector Clinical Trials, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-09-03 · NCT07684235Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-03 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
- Palm Research Center Inc, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-09-03 · NCT07684144Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
- Kailera Clinical Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-01 · NCT07284979Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Excel Clinical Research, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 99 · Visoms lytims · Atnaujinta 2026-08-27 · NCT07575399Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.
- University of Nevada, Las Vegas, Las Vegas
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 21 iki 74 · Visoms lytims · Atnaujinta 2026-08-27 · NCT07566325A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-25 · NCT07784725A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
- UMC of Southern Nevada, Las Vegas
- Palm Research Center Inc-Vegas, Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-18 · NCT07567001Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Las Vegas
Renkami dalyviai3 fazė
Amžius nuo 18 iki 79 · Visoms lytims · Atnaujinta 2026-08-10 · NCT07654361A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia
- Palm Research Center, Mountainview Medical Center, Las Vegas
Renkami dalyviai2 fazė
Amžius nuo 18 iki 80 · Visoms lytims · Atnaujinta 2026-07-22 · NCT07477704A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain
- Jubilee Clinical Research, Inc., Las Vegas
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-07-09 · NCT07481630A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets
- Corxel Investigational site, Las Vegas
Renkami dalyviai1 fazė
Amžius nuo 18 iki 55 · Moterims · Atnaujinta 2026-06-17 · NCT07652047Randomized Trial of Healthy Family Foundations
- Nellis Airforce Base, Nellis Air Force Base
Renkami dalyviaiLaukiami sveiki savanoriai
Amžius nuo 18 iki 60 · Visoms lytims · Atnaujinta 2026-04-14 · NCT05630482Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.